tradingkey.logo

Biomerica Inc

BMRA
2.250USD
-0.020-0.88%
Fechamento 02/06, 16:00ETCotações atrasadas em 15 min
6.63MValor de mercado
PerdaP/L TTM

Mais detalhes de Biomerica Inc Empresa

Biomerica, Inc. is a biomedical technology company that develops, patents, manufactures and markets advanced diagnostic and therapeutic products. Its diagnostic test kits are utilized in the analysis of blood, urine, nasal, or fecal samples for the diagnosis of various diseases, food intolerances, and other medical conditions. Its range of medical diagnostic products is sold primarily in two markets: clinical laboratories and point-of-care settings, including physicians’ offices and over-the-counter sales. It is focused on research and development efforts and is its patented diagnostic-guided therapy (DGT) product, developed on the in Foods technology platform. Its inFoods IBS product, uses a simple blood test to identify patient-specific foods that, when eliminated, may alleviate IBS symptoms such as pain, bloating, diarrhea, cramping, and constipation. Its hp+detect, a new diagnostic test for detecting Helicobacter pylori (H. pylori) bacteria in the gastrointestinal tract.

Informações de Biomerica Inc

Código da empresaBMRA
Nome da EmpresaBiomerica Inc
Data de listagemMar 17, 1980
CEOIrani (Zackary S)
Número de funcionários53
Tipo de títulosOrdinary Share
Fim do ano fiscalMar 17
Endereço17571 Von Karman Avenue
CidadeIRVINE
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited States of America
Código postal92614
Telefone19493792875
Sitehttps://biomerica.com/
Código da empresaBMRA
Data de listagemMar 17, 1980
CEOIrani (Zackary S)

Executivos da empresa Biomerica Inc

Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Zackary S. Irani
Mr. Zackary S. Irani
Chief Executive Officer, Director
Chief Executive Officer, Director
219.13K
+52500.00%
Mr. Gary Lu
Mr. Gary Lu
Chief Financial Officer
Chief Financial Officer
64.53K
+40000.00%
Mr. David Moatazedi
Mr. David Moatazedi
Independent Director
Independent Director
41.25K
+20000.00%
Mr. Eric Chin
Mr. Eric Chin
Independent Director
Independent Director
32.50K
+22500.00%
Mr. Allen C. Barbieri
Mr. Allen C. Barbieri
Executive Vice Chairperson of the Board and Corporate Secretary
Executive Vice Chairperson of the Board and Corporate Secretary
--
--
Dr. Jane F. Emerson, M.D., Ph.D.
Dr. Jane F. Emerson, M.D., Ph.D.
Independent Director
Independent Director
--
--
Mr. Scott Madel
Mr. Scott Madel
Chief Commercial Officer
Chief Commercial Officer
--
--
Mr. Gary M. Huff
Mr. Gary M. Huff
Independent Director
Independent Director
--
--
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Zackary S. Irani
Mr. Zackary S. Irani
Chief Executive Officer, Director
Chief Executive Officer, Director
219.13K
+52500.00%
Mr. Gary Lu
Mr. Gary Lu
Chief Financial Officer
Chief Financial Officer
64.53K
+40000.00%
Mr. David Moatazedi
Mr. David Moatazedi
Independent Director
Independent Director
41.25K
+20000.00%
Mr. Eric Chin
Mr. Eric Chin
Independent Director
Independent Director
32.50K
+22500.00%
Mr. Allen C. Barbieri
Mr. Allen C. Barbieri
Executive Vice Chairperson of the Board and Corporate Secretary
Executive Vice Chairperson of the Board and Corporate Secretary
--
--
Dr. Jane F. Emerson, M.D., Ph.D.
Dr. Jane F. Emerson, M.D., Ph.D.
Independent Director
Independent Director
--
--

Detalhamento da receita

Moeda: USDAtualizado em: ter, 6 de jan
Moeda: USDAtualizado em: ter, 6 de jan
FY2026Q1
FY2025
FY2025Q4
FY2025Q3
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2021
FY2020
Por EmpresaUSD
Nome
Receita
Proporção
Clinical Lab
1.02M
74.20%
Contract Manufacturing
192.00K
13.91%
OTC
161.00K
11.67%
Physicians’ Office
3.00K
0.22%
Por RegiãoUSD
Nome
Receita
Proporção
Asia
670.00K
48.55%
United States
318.00K
23.04%
Europe
305.00K
22.10%
Middle East
85.00K
6.16%
South America
2.00K
0.14%
Por Empresa
Por Região
Por EmpresaUSD
Nome
Receita
Proporção
Clinical Lab
1.02M
74.20%
Contract Manufacturing
192.00K
13.91%
OTC
161.00K
11.67%
Physicians’ Office
3.00K
0.22%

Distribuição de ações

Atualizado em: dom, 25 de jan
Atualizado em: dom, 25 de jan
Investidores
Tipos de investidores
Investidores
Investidores
Proporção
Irani (Zackary S)
7.26%
Barbieri (Allen)
2.23%
Lu (Gary)
2.14%
Moatazedi (David)
1.37%
Chin (Eric)
1.08%
Outro
85.94%
Investidores
Investidores
Proporção
Irani (Zackary S)
7.26%
Barbieri (Allen)
2.23%
Lu (Gary)
2.14%
Moatazedi (David)
1.37%
Chin (Eric)
1.08%
Outro
85.94%
Tipos de investidores
Investidores
Proporção
Individual Investor
15.59%
Investment Advisor
1.98%
Investment Advisor/Hedge Fund
0.76%
Hedge Fund
0.35%
Research Firm
0.03%
Outro
81.28%

Participação acionária institucional

Atualizado em: seg, 8 de dez
Atualizado em: seg, 8 de dez
Período do relatório
N.º de instituições
Ações detidas
Proporção
Variação
2025Q4
61
88.80K
11.10%
--
2025Q3
66
109.78K
12.53%
+19.30K
2025Q2
64
90.48K
15.22%
-57.30K
2025Q1
68
147.78K
21.33%
-341.18K
2024Q4
67
244.57K
22.09%
-15.39K
2024Q3
66
259.96K
25.76%
-100.07K
2024Q2
66
360.04K
29.98%
-224.63K
2024Q1
64
584.66K
28.76%
-20.09K
2023Q4
60
562.02K
30.44%
-39.83K
2023Q3
60
602.09K
33.14%
-52.42K
Ver Mais

Atividade dos acionistas

Nome
Ações detidas
Proporção
Variação
Var. %
Data
Irani (Zackary S)
219.13K
7.43%
+52.50K
+31.51%
Dec 12, 2025
Barbieri (Allen)
67.29K
2.28%
+30.00K
+80.44%
Dec 12, 2025
Lu (Gary)
64.53K
2.19%
+40.00K
+163.05%
Dec 12, 2025
Moatazedi (David)
41.25K
1.4%
+20.00K
+94.12%
Dec 12, 2025
Chin (Eric)
10.00K
0.34%
--
--
Oct 17, 2025
Emerson (Jane)
30.13K
1.02%
+30.13K
--
Oct 17, 2025
The Vanguard Group, Inc.
21.13K
0.72%
--
--
Sep 30, 2025
Geode Capital Management, L.L.C.
20.98K
0.71%
-680.00
-3.14%
Sep 30, 2025
BlackRock Institutional Trust Company, N.A.
18.64K
0.63%
--
--
Sep 30, 2025
Coste (Catherine)
16.10K
0.55%
+10.63K
+194.10%
Dec 13, 2024
Ver Mais

ETFs Relacionados

Nome
Proporção
Sem dados

Dividendo

Um total de 0.00 USD foi distribuído em dividendos nos últimos 5 anos.
Data
Dividendo
Data de registro
Data de pagamento
Data ex-dividendo
Sem dados

Desdobramento de ações

Data
Data ex-dividendo
Tipo
Proporção
Apr 16, 2025
Merger
8→1
Data
Data ex-dividendo
Tipo
Proporção
Apr 16, 2025
Merger
8→1
KeyAI